India, June 11 -- Dr. Philip Werschler, dermatologist and clinical investigator for AbbVie Inc. (ABBV)'s investigational TrenibotulinumtoxinE program, that received a Complete Response Letter, or CRL, from the U.S. Food and Drug Administration (FDA), provided an update on how complete response letters work and also on what a Serotype E Toxin could add to the category.
TrenibotE is an investigational botulinum neurotoxin serotype E (BoNT/E) neuromodulator, also known as "TrenibotulinumtoxinE," in evaluation for the treatment of glabellar lines (fine lines in the area between eyebrows just above the nose), which is potentially characterised for a rapid onset after administration as per published descriptions. In April 2026, AbbVie received a...